Finance

Lists
Why is MDMA down 10,00%?
Dive Deeper
MDMA:CNSX
Pharmala Biotech Holdings Inc
0,18 CA$
-10,00%
(-0,020) 1D
15 қаз., 16:00:00 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for MDMA...
Open
0,20 CA$
High
0,20 CA$
Low
0,18 CA$
Mkt. cap
19,55 млн
Avg. vol.
164,30 м.
Volume
220,16 м.
52-wk high
0,33 CA$
52-wk low
0,08 CA$
EPS
-0,02 CA$
No. of employees
3
Open
0,20 CA$
High
0,20 CA$
Low
0,18 CA$
Mkt. cap
19,55 млн
Avg. vol.
164,30 м.
Volume
220,16 м.
52-wk high
0,33 CA$
52-wk low
0,08 CA$
EPS
-0,02 CA$
No. of employees
3
News stories
From web sources and news partners
About Pharmala Biotech Holdings Inc
CEO-
Employees3
Founded2021
HeadquartersТоронто, Онтарио, Канада
Sector-
Last report
2026 ж. 29 шіл.
Fiscal period
Q3 2026
- / -
Revenue / Est. (CAD)
513,23 м. / -
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
2025 ж. там.
2025 ж. қар.
2026 ж. ақп.
2026 ж. мам.
Revenue
267,38 м.
206,44 м.
280,58 м.
513,23 м.
Cost of goods sold
34,04 мың
34,84 мың
22,41 мың
174,69 м.
Cost of revenue
34,04 мың
34,84 мың
22,41 мың
174,69 м.
Research and development expenses
44,91 мың
41,10 мың
40,53 мың
44,91 мың
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
404,68 м.
320,96 м.
367,29 м.
472,32 м.
Operating expense
553,47 м.
498,41 м.
559,82 м.
810,59 м.
Total operating expenses
587,50 м.
533,25 м.
582,22 м.
985,28 м.
Operating income
-320,13 м.
-326,81 м.
-301,64 м.
-472,05 м.
Other non operating income
-41,00 мың
-16,84 мың
-46,18 мың
-40,97 мың
EBT including unusual items
-361,13 м.
-409,70 м.
-337,70 м.
-499,76 м.
EBT excluding unusual items
-361,13 м.
-343,65 м.
-347,82 м.
-513,01 м.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-361,13 м.
-409,70 м.
-337,70 м.
-499,76 м.
Net profit margin
-135,07%
-198,46%
-120,35%
-97,37%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
29,19 мың
29,76 мың
29,74 мың
30,02 мың
EBITDA
-306,98 м.
-313,10 м.
-287,95 м.
-458,08 м.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары